-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Benzinga·08/07/2026 17:00:38
Listen to the news
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.